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Background
Familial Mediterranean fever (FMF) is the prototype of
chronic auto-inflammatory diseases. During the FMF
attacks there is an uncontrolled activation of an inflam-
matory cascade with a consequent release of many pro-
inflammatory molecules, which subsides or slows down
in between the attacks. Chronic inflammation has been
found to be associated with higher incidence of athero-
sclerotic cardiovascular disease (CVD). Thus, being a
chronic inflammatory disorder, it is speculated that FMF
may be considered as an independent risk factor for
CVDs. Most studies looking at the association between
FMF and CVDs have focused on markers, suggesting
increased atherosclerosis in FMF as compared to the
general population. Yet, these studies yielded conflicting
results. In the present study we analyze atherosclerosis
morbidity in FMF, by comparing affected to unaffected
FMF patients.
Objective
To determine FMF related and other underlying factors
leading to cardiovascular disease in FMF.
Methods
All files of colchicine treated FMF patients, 50 years old
or less, cared for in Sheba Medical Center (the largest
FMF Center in Israel, with registered FMF population
larger than 10000 patients), as in patients or FMF clinic
outpatients, over the last 10 years, bearing a diagnosis of
cerebral, cardiac or peripheral vascular disease were
pulled out and reviewed. For each studied patient 2 FMF
control subjects were adjusted from patients arriving to
FMF clinic for their periodic follow up visit. Our end-
points were: 1. Incidence of FMF related (without addi-
tional risk factors) CVD in this population compared to
the general population 2. Elucidation of FMF related and
unrelated risk factors for CVD in FMF. FMF severity, one
of the FMF related factors studied, was assessed using
the severity score-2 (SS-2) by Mor et. Al.
Results
There was only one FMF patient younger than 50 year old,
who suffered of CVD and had none of the traditional risk
factors. All other FMF patients with CV morbidity (23
cases) had other risk factors for CV disease. Compared
with the control FMF subjects, none of the assessed FMF
related parameters, including increased disease severity,
was more common in FMF-CVD. However, in the FMF-
CVD cohort, the rate of other inflammatory diseases was
higher.
Conclusion
These findings suggest that in colchicine treated FMF
population younger than 50 years of age, FMF per se is
not a risk factor for CVD.
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